Daewoong Pharmaceutical announced plans to construct a sterile manufacturing facility for microneedles at its Daewoong Bio Plant 3 in Hwaseong, Gyeonggi Province. The new infrastructure will support the production of microneedle-based pharmaceutical products. This investment underscores Daewoong Pharmaceutical's commitment to advancing drug delivery technologies. The company aims to establish a leading position in the microneedle market with the new facility. The sterile manufacturing environment will ensure the highest quality standards for these innovative products. Construction is expected to be completed soon, allowing Daewoong Pharmaceutical to rapidly scale up microneedle production and meet growing demand. The facility will contribute to advancements in transdermal drug delivery systems.